Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexpropranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL10537386 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL1561135 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL12264958 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL29577201 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL3956 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL3955 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL29355940 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL6511347 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL22291223 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL20486000 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16582 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083719-A1 | METHODS AND PRODUCTS FOR IMPROVING SPERM QUALITY | THE UNIVERSITY OF ADELAIDE (AU) | 2026-03-26 | — | — | US | claimed |
| US-20260041823-A1 | IMPLANTABLE MATERIAL AND SYNTHESIS METHOD THEREFOR AND PROSTHETIC HEART VALVE | VENUS MEDTECH HANGZHOU INC (CN) | 2026-02-12 | — | — | US | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4655068-A1 | MIGRAINE THERAPY | MedImmune Limited (GB) | 2025-12-03 | — | — | EP | claimed |
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| US-12436095-B2 | Nanozeolites and their analytical use as chemosensors in biorelevant media | Karlsruher Institut für Technologie (DE) | 2025-10-07 | — | — | US | claimed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | claimed |
| US-20250228889-A1 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | LUENINGHOENER CATHERINE (US) | 2025-07-17 | — | — | US | claimed |
| US-20250223370-A1 | METHODS OF TREATING DISORDERS USING ANTI-NATRIURETIC PEPTIDE RECEPTOR 1 (NPR1) ANTIBODIES | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| EP-0120118-A1 | Constant release rate solid oral dosage formulations of cardiovascular drugs | VEREX LABORATORIES, INC. (US) | 1984-10-03 | — | — | EP | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| US-4460562-A | BLEND OF PLASTICIZER, HYDROLYZED POLYVINYL ALCOHOL, AND POLYVINYLPYRROLIDONE | KEY PHARMACEUTICALS, INC. (US) | 1984-07-17 | — | — | US | claimed |
| EP-0045334-B1 | PROPRANOLOL ANTIGEN CONJUGATES AND ANTIBODIES AND METHOD OF USING THEM | SYVA COMPANY (US) | 1984-03-14 | — | — | EP | claimed |
| EP-0070300-A4 | SOLID PHASE SYSTEM FOR LIGAND ASSAY. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0070300-A1 | SOLID PHASE SYSTEM FOR LIGAND ASSAY. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-01-26 | — | — | EP | claimed |
| WO-1982002601-A1 | SOLID PHASE SYSTEM FOR LIGAND ASSAY | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-08-05 | — | — | WO | claimed |
| EP-0005365-B1 | PYRANO AND THIOPYRANO (3,4-B) INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-01-06 | — | — | EP | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
| US-3930718-A | Electro-optic modulator | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1976-01-06 | — | — | US | claimed |